Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lomustine × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 23 Lymphoid 8 Thoracic 2 Sarcoma 2 Other hematologic neoplasm 2 Other solid neoplasm 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Interventions

Cisplatin 39 Pemetrexed 29 Carboplatin 23 Nivolumab 19 Gemcitabine 18 pembrolizumab 16 atezolizumab 13 Ipilimumab 10 Injections 10 Docetaxel 10 Cyclophosphamide 10 Bevacizumab 10 Radiotherapy 9 Oxaliplatin 9 Etoposide 9 tislelizumab 8 durvalumab 8 Specimen Handling 8 Paclitaxel 8 Filgrastim 8 Capecitabine 8 tremelimumab 7 lenvatinib 7 olaparib 6 niraparib 6 Vinorelbine 6 Vincristine 6 Immune Checkpoint Inhibitors 6 Biopsy 6 toripalimab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡